Crossmark Global Holdings Inc. Raises Stock Holdings in Cencora, Inc. (NYSE:COR)

Crossmark Global Holdings Inc. lifted its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 7.3% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,111 shares of the company's stock after purchasing an additional 2,517 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Cencora were worth $8,353,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. New Millennium Group LLC purchased a new position in Cencora during the 2nd quarter valued at about $26,000. TCTC Holdings LLC purchased a new position in Cencora during the 1st quarter valued at about $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora during the 1st quarter valued at about $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Cencora during the 2nd quarter valued at about $30,000. Finally, Concord Wealth Partners acquired a new stake in shares of Cencora during the 3rd quarter valued at about $30,000. 97.52% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

COR has been the topic of several recent analyst reports. UBS Group lifted their price target on Cencora from $275.00 to $285.00 and gave the stock a "buy" rating in a research report on Thursday. Robert W. Baird boosted their price objective on Cencora from $287.00 to $292.00 and gave the stock an "outperform" rating in a research note on Thursday. JPMorgan Chase & Co. boosted their price objective on Cencora from $280.00 to $287.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 21st. Bank of America reissued a "neutral" rating and issued a $245.00 price objective (down previously from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. Finally, StockNews.com lowered Cencora from a "strong-buy" rating to a "buy" rating in a research note on Friday, September 20th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $271.20.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the company's stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares in the company, valued at $67,223,750.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 15.80% of the stock is owned by corporate insiders.

Cencora Price Performance

COR stock traded up $0.68 during midday trading on Monday, reaching $249.09. 1,232,651 shares of the stock were exchanged, compared to its average volume of 1,409,097. The stock has a market capitalization of $49.08 billion, a PE ratio of 33.17, a P/E/G ratio of 1.61 and a beta of 0.44. Cencora, Inc. has a 52 week low of $191.11 and a 52 week high of $251.52. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.55. The company has a fifty day moving average price of $231.95 and a 200 day moving average price of $230.74.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be issued a dividend of $0.55 per share. The ex-dividend date is Friday, November 15th. This is an increase from Cencora's previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a yield of 0.88%. Cencora's payout ratio is presently 27.16%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.